Product InnovationStereotaxis is transforming its endovascular robotic offering with the addition of a new robot (GenesisX), new disposable (MAGiC), and platform optionality (new indications).
Regulatory ApprovalsSTXS received CE Mark approval in Europe for GenesisX, filed a 510(k) for the system and made progress with the EU and US regulatory reviews of its MAGiC catheter.
Revenue GrowthThe new product portfolio enables increased per-procedure revenue potential (3-5x current per procedure potential), reduces system adoption friction, and establishes a platform technology.